Biocorrx (BICX) Stock Price, News & Analysis

Company Overview

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

Key Stats

• Today's Range: $0.35 to $0.35
• 50-Day Range: $0.25 to $0.45
• 52-Week Range: $0.20 to $1.28
• Volume: 115 shs
• Average Volume: 5,282 shs
• Market Capitalization: $10.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Biocorrx Stock Analysis - MarketRank™

Biocorrx scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Biocorrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Biocorrx has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biocorrx is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biocorrx is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Biocorrx has been sold short.

Short Interest Ratio / Days to Cover

Biocorrx has a short interest ratio ("days to cover") of 0.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biocorrx has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biocorrx does not currently pay a dividend.

Dividend Growth

Biocorrx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: -1.00

News Sentiment

Biocorrx has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Biocorrx this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biocorrx insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.40% of the stock of Biocorrx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Biocorrx has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 7/28/2026
• Next Earnings (Estimated): 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:BICX
• CIK: 1443863
• Web: www.biocorrx.com
• Phone: (714) 462-4880
• Fax: N/A
• Employees: 3
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.44 million
• Net Margins: N/A
• Pretax Margin: -401.48%
• Return on Equity: N/A
• Return on Assets: -73.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.10

Sales & Book Value

• Annual Sales: $800 thousand
• Price / Sales: 12.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -0.74

Miscellaneous

• Outstanding Shares: 29,670,000
• Free Float: 23,318,000
• Market Cap: $10.38 million
• Optionable: Not Optionable
• Beta: 0.17